Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.59 |
| ▸ | CDK9 | P50750 | 7/20 | 0.58 |
| ▸ | CDK2 | P24941 | 6/20 | 0.58 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.58 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.58 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.58 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.58 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.58 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.58 |
| ▸ | CDC7 | O00311 | 6/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.52 |
| ▸ | RET | P07949 | 6/20 | 0.50 |
| ▸ | CDK1 | P06493 | 5/20 | 0.50 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.50 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.50 |
| ▸ | PIM1 | P11309 | 4/20 | 0.50 |
| ▸ | PRKACA | P17612 | 4/20 | 0.50 |
| ▸ | GSK3B | P49841 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27828924 | 0.76 | CAMKK2 (0.70) | CAMKK2CDK9CDK2CCNT1CCNA2 | |
| SCHEMBL3350167 | 0.76 | PDPK1 (0.60) | CDK9CDK2CCNT1CCNA2CDK5 | |
| SCHEMBL8939866 | 0.75 | CAMKK2 (0.76) | CAMKK2CDK9CDK2CDK5PDPK1 | |
| SCHEMBL13239588 | 0.74 | CDK1 (0.64) | CDK9CDK2CCNT1CCNA2CDK5 | |
| SCHEMBL8942167 | 0.74 | DYRK1A (0.59) | CDK9CDK2CCNT1CCNA2CDK5 | |
| SCHEMBL30563455 | 0.74 | NUDT1 (0.67) | CAMKK2CDK9CDK2CCNT1CCNA2 | |
| SCHEMBL7053843 | 0.74 | CAMKK2 (0.63) | CAMKK2CDK9CDK2CCNT1CCNA2 | |
| SCHEMBL8939859 | 0.74 | CAMKK2 (1.00) | CAMKK2CDK9CDK2CDK5PDPK1 | |
| SCHEMBL4376699 | 0.74 | AKT1 (0.63) | CAMKK2CDK9CDK2CCNT1CCNA2 | |
| SCHEMBL29364420 | 0.74 | PRKCI (0.63) | CDK9CDK2CCNT1CCNA2CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180370966-A1 | METHODS OF TREATMENT USING PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2018-12-27 | — | — | US | disclosed |
| US-9873693-B2 | Methods of treatment using pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-8778977-B2 | Pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| EP-2038272-B1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHAMACEUTICALS (US) | 2010-06-10 | — | — | US | disclosed |
| EP-2038272-A2 | PYRIDINONYL PDK1 INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008005457-A2 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370966-A1 | METHODS OF TREATMENT USING PYRIDINONYL PDK1 INHIBITORS | PDK1, PDK2, PDK3 | CAMKK2 327/4885CDK9 341/4885CDK2 114/4885 |
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | PDK1, PDK2, PDK3 | CAMKK2 492/4885CDK9 98/4885CDK2 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.